Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.38 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13950090 | 0.95 | F10 (0.45) | F10ACHEDRD2HTR1A | |
| SCHEMBL14565158 | 0.92 | F10 (0.46) | F10ACHEDRD2CYP3A4CYP2D6 | |
| SCHEMBL4309398 | 0.89 | HSD17B10 (0.48) | F10ACHEALDH1A1HSD17B10 | |
| SCHEMBL4302265 | 0.89 | F10 (0.44) | F10ACHEDRD2CYP3A4CYP2D6 | |
| SCHEMBL4305991 | 0.87 | KMT2A (0.47) | F10ALDH1A1HSD17B10 | |
| SCHEMBL4308708 | 0.86 | F10 (0.45) | F10ACHECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13950073 | 0.85 | F10 (0.45) | F10CYP3A4CYP2C9ALDH1A1HSD17B10 | |
| SCHEMBL13950077 | 0.84 | F10 (0.43) | F10ACHESTK33 | |
| SCHEMBL13950119 | 0.84 | F10 (0.60) | F10ACHEDRD2CYP3A4CYP2D6 | |
| SCHEMBL13950087 | 0.84 | HTR1A (0.52) | F10ACHEDRD2HTR1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482472-B2 | Substituted isoindoles and their use | BAYER HEALTHCARE AG (DE) | 2009-01-27 | — | — | US | disclosed |
| US-7482472-B2 | Substituted isoindoles and their use | BAYER HEALTHCARE AG (DE) | 2009-01-27 | — | — | US | disclosed |
| US-7482472-B2 | Substituted isoindoles and their use | BAYER HEALTHCARE AG (DE) | 2009-01-27 | — | — | US | disclosed |
| US-20080039446-A1 | Substituted isoindoles and their use | BAYER HEALTHCARE AG (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039446-A1 | Substituted isoindoles and their use | BAYER HEALTHCARE AG (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039446-A1 | Substituted isoindoles and their use | BAYER HEALTHCARE AG (DE) | 2008-02-14 | — | — | US | disclosed |
| US-7189738-B2 | Substituted isoindoles and their use thereof | BAYER HEALTHCARE AG (DE) | 2007-03-13 | — | — | US | disclosed |
| US-7189738-B2 | Substituted isoindoles and their use thereof | BAYER HEALTHCARE AG (DE) | 2007-03-13 | — | — | US | disclosed |
| US-7189738-B2 | Substituted isoindoles and their use thereof | BAYER HEALTHCARE AG (DE) | 2007-03-13 | — | — | US | disclosed |
| EP-1414817-B1 | substituted isoindoles and the use thereof | BAYER HEALTHCARE AG (DE) | 2005-04-06 | — | — | EP | disclosed |
| US-20040215019-A1 | Substituted isoindoles and the e use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-10-28 | — | — | US | disclosed |
| EP-1414817-A1 | SUBSTITUTED ISOINDOLES AND E USE THEREOF | Bayer HealthCare AG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003011858-A1 | SUBSTITUTED ISOINDOLES AND E USE THEREOF | BAYER HEALTHCARE AG (DE) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039446-A1 | Substituted isoindoles and their use | F2, F12, TFPI2 | F10 19/4885ACHE 1206/4885DRD2 1154/4885 |
| US-20040215019-A1 | Substituted isoindoles and the e use thereof | F2, F12, F5 | F10 14/4885ACHE 1270/4885DRD2 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.